The BALB/cJ IL-4 Ra KO mouse was generated by Nancy Noben-Trauth at Jackson Laboratory in 1997 and analyzed in the Laboratory of Immunology, NIAID, NIH with Hua Gua and William Paul. The targeting vector, which deleted exons 6-9 of the gene, was transfected into BALB/c-I ES cells (derived by Birgit Ledermann at Novartis Pharmaceuticals). The chimeric founders were crossed to BALB/cJ mice and then intercrossed to generate offspring homozygous for the targeted allele. The IL-4Ra-/- mice are therefore a genetically pure BALB/cJ strain. The line was derived by embryo transfer into the NIAID barrier facility at Taconic in 2000.
Noben-Trauth N, et al.: An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice; Proc. Natl. Acad. Sci, USA, 1997:94(9):10838-43.
Noben-Trauth N, Paul WE, and Sacks DL: IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains; J. Immunolo. 1999:162(10):6132-40.
Noben-Trauth, N., J.Hu-Li, and W. E. Paul. 2000. Conventional, naïve CD4+ T cells provide an initial source of IL-4 during Th2 differentiation; J. Immunolo. 165:3620-3625.